About us

GADx is the home of innovations in lateral flow technology. We are a leading developer of lateral flow and rapid diagnostic technologies with a strong sense of purpose in Global Health, impact-led programmes, and local manufacturing. GADx was bought out from private investment in 2021 and is now led by a group of philanthropic stakeholders including ELMA philanthropies, Open Society Foundation, Skagen, and Sapling family investment groups. As part of this transition, GADx became a social enterprise, dedicating its profits and mission to improving the health and well-being of underserved populations worldwide.

Our 41 scientists are at the forefront of human, animal, and agricultural diagnostics. What’s more, your partnership with us has an impact beyond the world-class test we develop together. All of our profits are re-invested in developing affordable diagnostics for neglected issues and populations, so your investment helps to address the lack of access to diagnostics that the Lancet Commission estimates contributes to 1.1 million premature deaths annually.

The standard ISO 13485 is hugely important to designers, developers, and manufacturers of medical devices as it provides a solution to meet the requirements for a Quality Management System (QMS). Mologic Ltd t/a Global Access Diagnostics (GADx) is certified to ISO 13485:2016 & EN ISO 13485:2016.